Corbus Pharmaceuticals (CRBP)
(Real Time Quote from BATS)
$18.96 USD
-0.55 (-2.82%)
Updated Sep 23, 2024 10:16 AM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
CRBP 18.96 -0.55(-2.82%)
Will CRBP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRBP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRBP
Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why
CRBP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade
Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength
What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'
Other News for CRBP
Mizuho recommends buying Corbus following its drop post-Novo's obesity data
Corbus Pharma plunges 60% following Novo Nordisk weight loss drug data
Cannabis Stock Movers For September 20, 2024
Corbus sinks 61% to $20 after Novo Nordisk weight loss data
Skye Bioscience, Corbus sink after Novo weight loss data